Compare MBI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MBI | CTNM |
|---|---|---|
| Founded | 1973 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.2M | 328.1M |
| IPO Year | 1987 | 2024 |
| Metric | MBI | CTNM |
|---|---|---|
| Price | $7.53 | $10.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.50 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 319.3K | 181.8K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 285.71 | N/A |
| 52 Week Low | $3.86 | $3.35 |
| 52 Week High | $8.26 | $15.40 |
| Indicator | MBI | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 50.19 |
| Support Level | $7.34 | $10.19 |
| Resistance Level | $7.81 | $13.09 |
| Average True Range (ATR) | 0.27 | 0.84 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 40.00 | 31.55 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.